I tilfælde af en vedvarende klinisk relevant forhøjelse af transaminaseniveauerne bør dosisreduktion eller seponering af behandlingen overvejes.
However, in the event of persistent clinically relevant elevation of transaminase levels, reduction of the dose or discontinuation of treatment should be considered.